Switch theme
Sign up to access all valuation multiples
Shanghai Allist Pharmaceuticals Co Ltd is an innovative drug company in the field of cancer treatment.
2004
n/a
LTM Revenue $558M
LTM EBITDA $240M
$5.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shanghai Allist has a last 12-month revenue (LTM) of $558M and a last 12-month EBITDA of $240M.
In the most recent fiscal year, Shanghai Allist achieved revenue of $494M and an EBITDA of $230M.
Shanghai Allist expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai Allist valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $558M | XXX | $494M | XXX | XXX | XXX |
| Gross Profit | $535M | XXX | $474M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | $240M | XXX | $230M | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 47% | XXX | XXX | XXX |
| EBIT | $240M | XXX | $213M | XXX | XXX | XXX |
| EBIT Margin | 43% | XXX | 43% | XXX | XXX | XXX |
| Net Profit | $216M | XXX | $198M | XXX | XXX | XXX |
| Net Margin | 39% | XXX | 40% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Shanghai Allist's stock price is CNY 98 (or $14).
Shanghai Allist has current market cap of CNY 44.1B (or $6.1B), and EV of CNY 40.5B (or $5.6B).
See Shanghai Allist trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.6B | $6.1B | XXX | XXX | XXX | XXX | $0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Shanghai Allist has market cap of $6.1B and EV of $5.6B.
Shanghai Allist's trades at 11.4x EV/Revenue multiple, and 24.4x EV/EBITDA.
Equity research analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shanghai Allist has a P/E ratio of 28.3x.
See valuation multiples for Shanghai Allist and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.1B | XXX | $6.1B | XXX | XXX | XXX |
| EV (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV/Revenue | 10.1x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | 23.4x | XXX | 24.4x | XXX | XXX | XXX |
| EV/EBIT | 23.4x | XXX | 26.3x | XXX | XXX | XXX |
| EV/Gross Profit | 10.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.3x | XXX | 30.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 31.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShanghai Allist's last 12 month revenue growth is 26%
Shanghai Allist's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Shanghai Allist's rule of 40 is 60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shanghai Allist's rule of X is 108% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shanghai Allist and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 67% | XXX | XXX | XXX |
| Rule of 40 | 60% | XXX | 73% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 108% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai Allist acquired XXX companies to date.
Last acquisition by Shanghai Allist was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Allist acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shanghai Allist founded? | Shanghai Allist was founded in 2004. |
| Where is Shanghai Allist headquartered? | Shanghai Allist is headquartered in China. |
| Is Shanghai Allist publicy listed? | Yes, Shanghai Allist is a public company listed on SHG. |
| What is the stock symbol of Shanghai Allist? | Shanghai Allist trades under 688578 ticker. |
| When did Shanghai Allist go public? | Shanghai Allist went public in 2020. |
| Who are competitors of Shanghai Allist? | Similar companies to Shanghai Allist include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Shanghai Allist? | Shanghai Allist's current market cap is $6.1B |
| What is the current revenue of Shanghai Allist? | Shanghai Allist's last 12 months revenue is $558M. |
| What is the current revenue growth of Shanghai Allist? | Shanghai Allist revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Shanghai Allist? | Current revenue multiple of Shanghai Allist is 10.1x. |
| Is Shanghai Allist profitable? | Yes, Shanghai Allist is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shanghai Allist? | Shanghai Allist's last 12 months EBITDA is $240M. |
| What is Shanghai Allist's EBITDA margin? | Shanghai Allist's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Shanghai Allist? | Current EBITDA multiple of Shanghai Allist is 23.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
